Experts discuss the unique challenges of managing atopic dermatitis (AD) in pediatric and adolescent patients, emphasizing the strategic use of topical treatments to improve adherence, reduce ...
Experts discuss the importance of balancing effective symptom control with quality of life in managing chronic pediatric atopic dermatitis, emphasizing personalized treatment plans that address both ...
"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...
Stocktwits on MSN
Johnson & Johnson terminates experimental eczema drug study after it fails to show benefit
The drug JNJ-5939 was being evaluated in the treatment of moderate to severe atopic dermatitis in a mid-stage study. ・JNJ, ...
Please provide your email address to receive an email when new articles are posted on . Results showed high-dose upadacitinib was the most effective treatment, yet it increased any adverse event.
Johnson & Johnson (NYSE:JNJ) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 26, Johnson & ...
Back in October, the 2025 Fall Clinical Dermatology Conference showcased some of the most exciting advances in skin disease treatment this year. From pill-based TYK2 inhibitors and durable IL-23 ...
The company said the results of a planned interim analysis met prespecified criteria for early termination of the study. "They did not meet the high-bar efficacy we established for advancing our ...
This article was originally published in French on Medscape. PARIS — The 17th Congrès Francophone d'allergologie (CFA), a congress of French-speaking allergists, took place April 19-April 22 at the ...
Credit: Getty Images. Clinical phenotypes of atopic dermatitis can vary greatly based on skin color and can make atopic dermatitis difficult to diagnose. Recognizing the clinical diversity of ...
DelveInsight’s “Atopic Dermatitis Pipeline Insight 2025” report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in the Atopic Dermatitis pipeline landscape. It covers the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback